ACVR2B and clear cell renal carcinoma: Since then, the same potential of ACVR2B antagonists, including ACVR2B-Fc and other inhibitors, such as microRNA-194, has also been discovered in different cancers, including pancreatic cancer and clear cell kidney carcinoma [30,31].